BRUSSELS, June 1 (Reuters) - EU antitrust regulators will
decide by July 5 whether to clear Anglo-Swedish drugmaker
AstraZeneca's $39 billion bid for U.S.-based Alexion
, a European Commission filing showed on Tuesday.
AstraZeneca sought EU approval on Monday for the deal, its
largest ever in a bet on rare-disease immunology and to boost
its business, which includes a fast-growing cancer medicines
unit and a major COVID-19 vaccine.
The Commission can either clear the deal with or without
conditions or it can open a four-month long investigation if it
has serious concerns.
The UK Competition Authority and Markets Authority is also
reviewing the bid which has already received the green light in
the United States, Canada, Brazil and Russia.
(Reporting by Foo Yun Chee; editing by David Evans)